LLY
Eli Lilly and Company
LLY has the edge over MASS overall, supported by lower modeled downside and stronger valuation.
MASS
908 Devices Inc.
MASS's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MASS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
MASS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MASS PE Valuation
MASS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over MASS on the outlook, with more favorable earnings expectations.
MASS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MASS's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MASS on earnings quality, reporting a profit while its opponent remains loss making.
MASS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.53 |
| Q2 2026 | -$0.96 | -$0.40 |
| Q1 2026 | -$1.01 | -$0.45 |
| Q4 2025 | $0.54 | +$2.66 |
| Q3 2025 | -$0.13 | +$1.64 |
| Q2 2025 | -$0.56 | +$0.59 |
| Q1 2025 | -$0.56 | +$0.51 |
| Q4 2024 | -$2.12 | -$0.99 |
MASS is still losing money, but far less than before: $0.66 per share over the past year, against $2.12 at its worst in late 2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MASS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MASS on profitability, with a higher operating margin.
MASS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +35% |
| Q2 2026 | $16.1M | +23% |
| Q1 2026 | $13.4M | +14% |
| Q4 2025 | $17.4M | -7.7% |
| Q3 2025 | $14M | -17% |
| Q2 2025 | $13M | -7.2% |
| Q1 2025 | $11.8M | +18% |
| Q4 2024 | $18.8M | +31% |
MASS's revenue is growing: $19M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -29% | +88 points |
| Q2 2026 | -80% | +37 points |
| Q1 2026 | -96% | -2.7 points |
| Q4 2025 | 18% | +125 points |
| Q3 2025 | -117% | +64 points |
| Q2 2025 | -116% | -20 points |
| Q1 2025 | -94% | +33 points |
| Q4 2024 | -108% | -40 points |
MASS's operating margin was −29% last quarter, up 88 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
MASS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.9M | +$2M |
| Q2 2026 | $3M | +$8.9M |
| Q1 2026 | $1.2M | +$16.3M |
| Q4 2025 | $1.3M | +$3.8M |
| Q3 2025 | -$4.9M | +$879K |
| Q2 2025 | -$5.9M | +$6.5M |
| Q1 2025 | -$15.2M | -$4.9M |
| Q4 2024 | -$2.4M | -$170K |
MASS's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MASS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MASS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.9% | +3.3M shares |
| 1 year | +14% | +5M shares |
| 3 years | +27% | +8.7M shares |
| 5 years | +48% | +13.4M shares |
| Available history | +492% | +34.1M shares |
MASS has 41M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MASS Net Leverage
MASS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MASS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.5 | Neutral |
| Stochastic | 46.7 | Neutral |
MASS's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MASS PE vs Healthcare Sector
MASS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MASS on trend strength, trading above more of its moving averages.
MASS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 14% below |
| 20 week MA | $10.0 | 2.2% below |
| 50 week MA | $8.06 | 21% above |
| 100 week MA | $6.71 | 46% above |
| 200 week MA | $6.59 | 49% above |
MASS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 49% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
MASS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $67.9 | +39% |
| 2021 | $67.9 | $26.6 | -61% |
| 2022 | $26.6 | $7.31 | -73% |
| 2023 | $7.31 | $11.2 | +53% |
| 2024 | $11.2 | $2.26 | -80% |
| 2025 | $2.26 | $5.41 | +139% |
| 2026 YTD | $5.41 | $9.79 | +81% |
MASS has the edge over LLY on returns for 2026, with the stronger performance.